Medicinal Plant Research 2025, Vol.15, No.5, 233-243 http://hortherbpublisher.com/index.php/mpr 239 Figure 2 Candidate SM extracted-related metabolic networks in AMI rats. (A) Impaired metabolic networks in control vs. AMI cohort. (B) Impaired metabolic networks in AMI vs. SM-1.8 g/kg cohort. The size and color of individual circles represent significance of network stratified by p-value (red: enhanced p-values and yellow: diminished p-values) and network impact score (larger circle = higher impact score), respectively. (C) An illustration of the estimated metabolic networks (Adopted from Mu et al., 2024) 7.2 The efficacy and mechanism of A. membranaceus andS. miltiorrhiza combination on MI Myocardial ischemia (MI) is one of the leading cardiovascular diseases, which causing death and disability worldwide. Despite the development of various treatment methods in modern medicine, there are still limitations, especially in terms of myocardial reperfusion, and long-term cardiac function recovery. Traditional Chinese medicine (TCM) has a long history in the treatment of cardiovascular diseases. Many plant medicinal materials have been found to have the effects of promoting angiogenesis and protecting the heart (Hung, 2019; Lin et al., 2021; Zhang et al., 2023). Zhang et al. (2023) explored the therapeutic effect and mechanism of the TCM combination "A. membranaceus and S. miltiorrhiza (AS)" on myocardial ischemia (MI). The study used a mouse model of MI, induced by ligation of the left anterior descending coronary artery (LAD), and found that AS could reduce MI area, improve cardiac function, including restoring abnormal electrocardiogram, increasing ejection fraction and shortening fraction, and reducing the levels of heart failure markers BNP and NT-proBNP. Histological analysis shows that, AS can also alleviate myocardial pathological damage, such as reducing infarction area, myocardial remodeling and fibrosis. Importantly, the research mechanism reveals that, AS promotes angiogenesis by facilitating pericytes recruitment and upregulating factors, like vascular endothelial cadherin, VEGF, and TGF-β. Its mode of action is related to the Ang-1/Tie-2/FAK signaling pathway (Figure 3). These findings indicate that AS is expected to become a novel adjuvant therapy for myocardial ischemia, and has broad application prospects.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==